InMed Pharmaceuticals Files 8-K
Ticker: INM · Form: 8-K · Filed: Aug 21, 2024 · CIK: 1728328
Sentiment: neutral
Topics: regulatory-filing, 8-k
TL;DR
InMed Pharma filed an 8-K, standard procedure, no major news.
AI Summary
InMed Pharmaceuticals Inc. filed an 8-K on August 21, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates InMed Pharmaceuticals Inc. is meeting its regulatory reporting obligations with the SEC.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for regulatory compliance and does not disclose any new material events or financial information.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Filer of the 8-K report
- August 21, 2024 (date) — Date of the earliest event reported
FAQ
What is the primary purpose of this 8-K filing for InMed Pharmaceuticals Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on August 21, 2024.
What is the exact name of the company filing this report?
The exact name of the company is InMed Pharmaceuticals Inc.
In which jurisdiction was InMed Pharmaceuticals Inc. incorporated?
InMed Pharmaceuticals Inc. was incorporated in British Columbia.
What is the principal executive office address for InMed Pharmaceuticals Inc.?
The principal executive office address is Suite 1445 - 885 W. Georgia Street, Vancouver, B.C. Canada V6C 3E8.
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-08-21 14:04:20
Filing Documents
- ea0212056-8k_inmed.htm (8-K) — 40KB
- ea021205601ex99-1_inmed.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-071386.txt ( ) — 278KB
- inm-20240821.xsd (EX-101.SCH) — 3KB
- inm-20240821_def.xml (EX-101.DEF) — 26KB
- inm-20240821_lab.xml (EX-101.LAB) — 35KB
- inm-20240821_pre.xml (EX-101.PRE) — 24KB
- ea0212056-8k_inmed_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated August 21, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: August 21, 2024 By: /s/ Eric A Adams Eric A Adams President & CEO 2